#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cutaneous T-cell lymphoma stage I Hepato-lenticular degeneration B-cell small lymphocytic lymphoma refractory Stargardt's disease Neoplasm Mantle cell lymphoma stage II KBG syndrome Granulomatosis with polyangiitis Necrotising myositis Brain injury Restless legs syndrome HER2 mutant non-small cell lung cancer Severe myoclonic epilepsy of infancy Malignant fibrous histiocytoma Bronchopulmonary dysplasia More trials…

    Learn about Rare Diseases

    Angiosarcoma metastatic – Basic Information Mantle cell lymphoma – Treatment Erdheim-Chester disease – Basic Information Angelman’s syndrome – Diagnostics Alternating hemiplegia of childhood – Trials in Disease Angiosarcoma non-metastatic – Treatment Encephalitis autoimmune – Basic Information Medulloblastoma recurrent – Trials in Disease Focal segmental glomerulosclerosis Haemophilia B with anti factor IX – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Abc-23B-116 Cellulose, Microcrystalline Df1001 [14C]ZIPALERTINIB Anb032 Codeine Phosphate Hemihydrate Tuparstobart ARTICAINE HYDROCHLORIDE 4-Hydroxy-N-Desmethyltamoxifen Aciclovir Emavusertib SARACATINIB Zoledronic Acid Dexketoprofen Eltrombopag Tryptophan Fulvestrant Monalizumab Latanoprost GRAPHITE More therapies…

    Learn about Your Condition

    Tuberculosis Osteoporosis Ligament operation Thrombosis Critical illness Vaginal haemorrhage Haemorrhage intracranial Skin bacterial infection Cerebellar ataxia Bladder cancer Colour blindness Bladder cancer stage II Fatty acid oxidation disorder Hairy cell leukaemia Osteomyelitis acute More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopitaux Universitaires Pitie Salpetriere

Hopitaux Universitaires Pitie Salpetriere

47 Boulevard De L Hopital, Paris, 75651, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients Without HIV

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Progressive multifocal leukoencephalopathy
    Investigated Drugs:
    • Pembrolizumab
    France

  • Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Uveitis
    Investigated Drugs:
    • Fluorescein Sodium
    • Indocyanine Green
    • Adalimumab
    France

  • Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

    Recruiting

    1 1 1
    Investigated Diseases:
    • Hereditary angioedema
    Investigated Drugs:
    • Lonvoguran
    • Ziclumeran
    France Germany The Netherlands

  • Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

    Recruiting

    3 1
    Investigated Diseases:
    • Hepatic fibrosis
    Investigated Drugs:
    • Efruxifermin
    France Germany Italy Poland Spain

  • Study on UCPVax, Atezolizumab, and Bevacizumab for Patients with Unresectable Liver Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ucp4
    • Atezolizumab
    • Bevacizumab
    France

  • Study Comparing CPX-351 and Chemotherapy for Patients with New Intermediate or High-Risk Acute Myeloid Leukemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Idarubicin
    • Cytarabine
    • Daunorubicin
    France

  • Study on Hydroxychloroquine and Prednisone for Patients with Non-Severe Extra-Pulmonary Sarcoidosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Sarcoidosis
    Investigated Drugs:
    • Hydroxychloroquine Sulfate
    • Prednisone
    France

  • Study Comparing Clofarabine/Busulfan and Fludarabine/Busulfan for Adults with Acute Myeloid Leukemia Eligible for Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
    • Ciclosporin
    • Clofarabine
    France

  • Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Camizestrant
    • Exemestane
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    France
Previous Page
1 … 5 6 7 8 9 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!